Pete Pharma

PETE Pharma is a preclinical-stage biotechnology company specializing in the development of polymer-based drug delivery systems designed to enhance the targeting and therapeutic index of various drugs. The company's core technology, the Polymer-Enhanced Targeted Therapeutics (PETE) platform, focuses on the delivery of small molecules and nucleic acids, particularly those targeting the CXCR4/SDF-1 signaling axis. This pathway is critical in the progression of metastatic cancer and chronic inflammatory diseases. Founded as a spin-out from the University of Nebraska Medical Center, PETE Pharma leverages advanced polymer chemistry to create multifunctional nanoparticles that improve drug stability and tissue-specific uptake. The company aims to translate its innovative delivery solutions into effective treatments for high-unmet-need conditions.